Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × zimberelimab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Uterine Cervical Neoplasms 8 Stomach Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Triple Negative Breast Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Lung Neoplasms 3 Carcinoma, Renal Cell 3 Advanced Solid Tumors 3 Urinary Bladder Neoplasms 2 Solid Tumor 2 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Kidney Neoplasms 2 Esophageal Neoplasms 2 Cholangiocarcinoma 2 Adenocarcinoma Of Esophagus 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumors 1 Solid Tumor, Unspecified, Adult 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1

Interventions

Cisplatin 11 Everolimus 10 Nivolumab 7 Etoposide 7 Temozolomide 5 Ipilimumab 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 atezolizumab 4 Irinotecan 4 Capecitabine 4 pembrolizumab 3 avelumab 3 Paclitaxel 3 Fluorouracil 3 surufatinib 2 sintilimab 2 gallium Ga 68 dotatate 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Positron Emission Tomography Computed Tomography 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 IFL protocol 2 Fluorodeoxyglucose F18 2 EC regimen 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07337447 2026-01-13

REWENEC 01

Hospices Civils de Lyon

Phase 2 Not yet recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡